Ion Beam Applications SA (IBAB.BR) Stock
Ion Beam Applications SA

Company profile
Ion Beam Applications SA reported revenue of 498.16 million EUR for fiscal year 2024, up 6.7% from fiscal year 2023. Our analysis of its filings shows revenue growing from 361.27 million EUR in fiscal year 2022 to 498.16 million EUR in fiscal year 2024, 17.4% a year on average. Ion Beam Applications SA reports about 2,264 full-time employees.
What stands out
- It returned to a profit in fiscal year 2024, 9.25 million EUR, after a net loss of 9.11 million EUR in fiscal year 2023.
- Revenue and net income in fiscal year 2024 were the highest of the last 4 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Ion Beam Applications SA
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Largest shareholders
- Sustainable Anchorage BV20.49%
- Vallcara Ltd.5.36%
- Government of Belgium4.70%
- Belfius Insurance SA NV3.93%
- Ion Beam Applications, SA3.39%
Share of the company, as of September 25, 2026
Leadership
- Olivier Legrain — CEO, MD & Vice Chairman, 57
- Henri de Romree — Deputy CEO, Internal Director & Managing Director, 49
- Bruno Scutnaire — President of IBA RadioPharma Solutions
- Catherine Vandenborre — CFO, Chief Ventures & Corporate Officer, 54
- Yves Jongen — Founder, Chief Research Officer & Executive Director, 78
In the news
- Brachytherapy Devices Market Growth Opportunities and Competitive Intelligence (2025-2030) Featuring Varian Medical Systems, Elekta, Ion Beam Applications, C. R. Bard, and Eckert & Ziegler Among Others
- iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone® 70
- IBA - Regulated Information
- IBA – Transparency Notification
How much revenue does Ion Beam Applications SA make?
Ion Beam Applications SA reported 498.16 million EUR in revenue for fiscal year 2024, up 6.7% from 466.67 million EUR in fiscal year 2023.
Has Ion Beam Applications SA made a profit in recent years?
Net income by fiscal year: FY2021, 3.88 million EUR; FY2022, 6.06 million EUR; FY2023, a loss of 9.11 million EUR; FY2024, 9.25 million EUR. It reported a net loss in 1 of these 4 years.
How has Ion Beam Applications SA's revenue changed over the last 4 fiscal years?
Revenue by fiscal year: FY2021, 312.96 million EUR; FY2022, 361.27 million EUR; FY2023, 466.67 million EUR; FY2024, 498.16 million EUR.
Company Information
Data as of .
How to cite: DataPorium, “Ion Beam Applications SA (IBAB.BR)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/IBAB.BR